SPRB

0.4734

3.51% -0.0172

Handel nachbörslich: .50 0.0266 +5.62%

Spruce Biosciences Inc (SPRB)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$0.4906

Offen:

$0.4875

24-Stunden-Volumen:

334.98K

Relative Volume:

0.87

Marktkapitalisierung:

$19.54M

Einnahmen:

$9.57M

Nettoeinkommen (Verlust:

$-43.11M

KGV:

-0.2835

EPS:

-1.67

Netto-Cashflow:

$-49.54M

1W Leistung:

-11.10%

1M Leistung:

-8.79%

6M Leistung:

-36.88%

1J Leistung:

-64.93%

1-Tages-Spanne:

$0.4726

$0.508

1-Wochen-Bereich:

$0.4726

$0.5365

52-Wochen-Spanne:

$0.4112

$5.95

Spruce Biosciences Inc Stock (SPRB) Company Profile

Firmenname

Spruce Biosciences Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

(415) 655-4168

Adresse

611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

SPRB's Discussions on Twitter

Vergleichen Sie SPRB mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SPRB	0.4734	19.54M	9.57M	-43.11M	-49.54M	-1.67
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-12-17	Eingeleitet	Oppenheimer	Outperform
2021-12-10	Eingeleitet	The Benchmark Company	Speculative Buy
2021-11-16	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-07-19	Eingeleitet	H.C. Wainwright	Buy
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2020-11-03	Eingeleitet	Cowen	Outperform
2020-11-03	Eingeleitet	Credit Suisse	Outperform
2020-11-03	Eingeleitet	RBC Capital Mkts	Outperform
2020-11-03	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Spruce Biosciences Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Spruce Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 14, 2024

Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace

Nov 14, 2024

Nov 13, 2024

Scholz Advisers Slash German Growth Forecast for Next Year - Yahoo Finance

Nov 13, 2024

EchoStar Q3 Earnings Lag Estimates on Lower Revenues, Stock Down 13% - Yahoo Finance

Nov 13, 2024

Spruce Biosciences' SWOT analysis: tildacerfont's fate hangs on Q4 trial results - Investing.com India

Nov 13, 2024

Spruce Biosciences Faces Nasdaq Delisting Threat: Can a Reverse Stock Split Save Its Market Presence? - TipRanks

Nov 13, 2024

Nov 12, 2024

US opens probe into 1.4 million Honda vehicles over engine issues - Yahoo Canada Finance

Nov 11, 2024

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - BioSpace

Nov 11, 2024

Why Cambium (CMBM) International Revenue Trends Deserve Your Attention - Yahoo Finance

Nov 11, 2024

Spruce Biosciences Trims Losses, Eyes Critical Clinical Data in December | SPRB Stock News - StockTitan

Nov 11, 2024

Nov 10, 2024

Don't Race Out To Buy Enbridge Inc. (TSE:ENB) Just Because It's Going Ex-Dividend - Yahoo Finance

Nov 10, 2024

Nov 09, 2024

Caribou Biosciences (NASDAQ:CRBU) vs. Sutro Biopharma (NASDAQ:STRO) Financial Analysis - Defense World

Nov 09, 2024

Brokerages Set Element Solutions Inc (NYSE:ESI) Target Price at $31.00 - Defense World

Nov 09, 2024

Vitro Diagnostics (OTCMKTS:VODG) and Tectonic Therapeutic (NASDAQ:TECX) Critical Comparison - Defense World

Nov 09, 2024

Analysts Set Spruce Biosciences, Inc. (NASDAQ:SPRB) Price Target at $5.00 - Defense World

Nov 09, 2024

Oct 29, 2024

Spruce Biosciences faces Nasdaq delisting notice - Investing.com India

Oct 29, 2024

Oct 28, 2024

Spruce Biosciences faces Nasdaq delisting notice By Investing.com - Investing.com South Africa

Oct 28, 2024

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference - Business Wire

Oct 28, 2024

Oct 22, 2024

Global Adrenogenital Syndrome Treatment Market to Reach USD 22.08 Billion in 2033, Driven by New The - PharmiWeb.com

Oct 22, 2024

Congenital Adrenal Hyperplasia Clinical Trials 2024: FDA Approvals, Companies, Medication, Treatment Market, Therapies, ROA and MOA by DelveInsight | Becton, Dickinson and Company, Cook Medical, MORE - Barchart

Oct 22, 2024

Oct 16, 2024

Floyd Mayweather Jr buying $402M Black Spruce portfolio - Yahoo Finance

Oct 16, 2024

Oct 15, 2024

Congenital Adrenal Hyperplasia (CAH) Therapeutic Market 2024 - openPR

Oct 15, 2024

Oct 12, 2024

Ambev S.A. (NYSE:ABEV) Given Average Rating of “Hold” by Brokerages - Defense World

Oct 12, 2024

Oct 10, 2024

Daily Progress: Spruce Biosciences Inc (SPRB) Drop -5.56, Closing at 0.43 - The Dwinnex

Oct 10, 2024

The Significance of Moving Averages in Spruce Biosciences Inc Inc. (SPRB) Price Performance - The InvestChronicle

Oct 10, 2024

Oct 03, 2024

A closer look at Spruce Biosciences Inc (SPRB)’s stock price trends - US Post News

Oct 03, 2024

Oct 02, 2024

North Carolina town that produces quartz needed for tech products is devastated by Helene - Yahoo Finance

Oct 02, 2024

Sep 30, 2024

Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock - Investing.com

Sep 30, 2024

Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock By Investing.com - Investing.com UK

Sep 30, 2024

Neurocrine Biosciences's Crinecerfont is Set to Transform the Congenital Adrenal Hyperplasia Treatment Market | DelveInsight - PR Newswire

Sep 30, 2024

Sep 24, 2024

Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily

Sep 24, 2024

Sep 20, 2024